Investigative Ophthalmology & Visual Science Cover Image for Volume 65, Issue 7
June 2024
Volume 65, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2024
Evaluation of Myocardial Infarction in Patients undergoing Anti-VEGF Treatment for Wet Macular Degeneration
Author Affiliations & Notes
  • James Raynor
    College of Medicine, Northeast Ohio Medical University, Rootstown, Ohio, United States
  • Isaiah Murray
    College of Medicine, Northeast Ohio Medical University, Rootstown, Ohio, United States
  • Jonathan Markle
    Cleveland Clinic Cole Eye Institute, Cleveland, Ohio, United States
  • Jacqueline K. Shaia
    Cleveland Clinic Cole Eye Institute, Cleveland, Ohio, United States
  • David Donghan Chong
    Case Western Reserve University School of Medicine, Cleveland, Ohio, United States
  • Thomas Cuchta
    Case Western Reserve University School of Medicine, Cleveland, Ohio, United States
  • Sophie Yue
    Case Western Reserve University School of Medicine, Cleveland, Ohio, United States
  • Katherine Talcott
    Cleveland Clinic Cole Eye Institute, Cleveland, Ohio, United States
  • Rishi Singh
    Cleveland Clinic Cole Eye Institute, Cleveland, Ohio, United States
  • Footnotes
    Commercial Relationships   James Raynor None; Isaiah Murray None; Jonathan Markle None; Jacqueline Shaia None; David Chong None; Thomas Cuchta None; Sophie Yue None; Katherine Talcott Alimera, Apellis, Bausch and Lomb, Eyepoint, Genentech , Code C (Consultant/Contractor), Regeneron, Regenxbio, Zeiss, Code F (Financial Support), Genentech, Iveric Bio, , Code S (non-remunerative); Rishi Singh Genentech/Roche, Alcon, Novartis, Regeneron, Asclepix, Gyroscope, Bausch and Lomb, Apellis, Code F (Financial Support)
  • Footnotes
    Support  P30EY025585(BA-A), Research to Prevent Blindness (RPB) Challenge Grant, Cleveland Eye Bank Foundation Grant; National Eye Institute: T32 EY024236 (Jacqueline Shaia); This project was supported by the Clinical and Translational Science Collaborative (CTSC) of Cleveland which is funded by the National Institutes of Health (NIH), National Center for Advancing Translational Science (NCATS), Clinical and Translational Science Award (CTSA) grant, UL1TR002548
Investigative Ophthalmology & Visual Science June 2024, Vol.65, 250. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      James Raynor, Isaiah Murray, Jonathan Markle, Jacqueline K. Shaia, David Donghan Chong, Thomas Cuchta, Sophie Yue, Katherine Talcott, Rishi Singh; Evaluation of Myocardial Infarction in Patients undergoing Anti-VEGF Treatment for Wet Macular Degeneration. Invest. Ophthalmol. Vis. Sci. 2024;65(7):250.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Anti-vascular endothelial growth factor (VEGF) intravitreal injections have become the mainstay treatment for patients with wet macular degeneration (wAMD). However, an increased risk of adverse cardiovascular events, such as myocardial infarction (MI), may be associated with the use of these injections. Few studies have examined the relationship between anti-VEGF injections and MI. This single-institution, retrospective observational study aims to assess the relationship between initial anti-VEGF injection treatment and the incidence of MI in patients being treated for wAMD.

Methods : Patients who had a history of anti-VEGF injections for treatment of wAMD and geographic atrophy (GA) patients who did not receive injections were obtained from the electronic medical records. A propensity analysis utilizing greedy 1:1 replacement was performed to match wAMD treated anti-VEGF patients to GA patients who had no history of injections. Patients were matched across age, sex, BMI, race/ethnicity, diabetes status, and tobacco use to evaluate the binary outcome of having an MI or not, with significance set at p<0.05.

Results : A total of 809 wAMD patients were matched to a GA control group of 316 patients. The prevalence of an MI was 2.8% in the GA population and 4.2% in the wAMD cohort. Patients had an average age of 80 in the wAMD group with 64% female and 82 in the GA control with 65% female. After matching, standardized differences indicated a successful match, defined as less than 0.10 or greater than -0.10. 809 distinct wAMD patients and 253 GA patients were utilized. A risk ratio of 0.74 (95% CI 0.46, 1.17) was found when comparing the intervention to the control group. The average time patients were followed was 29.47 months. The majority of patients continued to receive multiple injections throughout this observation period.

Conclusions : Overall, no difference was found in the risk of MI when comparing wAMD treated with anti-VEGF to GA patients not treated with anti-VEGF. More evidence-based research is needed to determine if a time-to-event association exists between the two variables.

This abstract was presented at the 2024 ARVO Annual Meeting, held in Seattle, WA, May 5-9, 2024.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×